

Frauke Mcksch

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2457967/frauke-mucksch-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52 papers	6,314 citations	27 h-index	62 g-index
62 ext. papers	10,074 ext. citations	28.4 avg, IF	6.19 L-index

#	Paper	IF	Citations
52	Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. 2022,		1
51	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. 2022,		3
50	Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry.. <i>ELife</i> , 2022 , 11,	8.9	4
49	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. <i>Immunity</i> , 2022,	32.3	10
48	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. <i>Nature</i> , 2022,	50.4	14
47	Plasma Neutralization of the SARS-CoV-2 Omicron Variant.. <i>New England Journal of Medicine</i> , 2021,	59.2	93
46	Plasma neutralization properties of the SARS-CoV-2 Omicron variant. 2021,		31
45	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021,	50.4	69
44	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	171
43	Evolution of Antibody Immunity to SARS-CoV-2 2021,		43
42	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies 2021,		24
41	Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants 2021,		8
40	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. <i>Nature</i> , 2021 , 593, 424-428	50.4	36
39	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies 2021,		27
38	Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry 2021,		9
37	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies 2021,		13
36	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year 2021,		19

35	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021 , 595, 426-431	50.4	247
34	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. <i>Cell</i> , 2021 , 184, 3205-3221.e24	50.4	24
33	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , 2021 , 595, 278-282	50.4	49
32	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. <i>New England Journal of Medicine</i> , 2021 , 384, 2212-2218	59.2	347
31	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. <i>PLoS Pathogens</i> , 2021 , 17, e1009688	7.6	7
30	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity 2021 ,		2
29	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021 , 12, 4196	17.4	106
28	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. <i>Journal of Infectious Diseases</i> , 2021 , 223, 389-398	7	136
27	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	178
26	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021 , 591, 639-644	50.4	652
25	Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease 2021 ,		2
24	Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial. <i>Transfusion</i> , 2021 , 61, 1363-1369	2.9	5
23	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021 , 592, 616-622	50.4	730
22	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021 , 54, 1853-1868.e7	32.3	83
21	Maturation of the matrix and viral membrane of HIV-1. <i>Science</i> , 2021 , 373, 700-704	33.3	10
20	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. <i>Cell Reports</i> , 2021 , 36, 109760	10.6	29
19	HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization. <i>Cell Host and Microbe</i> , 2021 , 29, 1421-1436.e7	23.4	5
18	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland.. <i>Journal of Clinical Virology Plus</i> , 2021 , 1, 100028		

17	A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques 2021 ,		1
16	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants 2021 ,		54
15	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020 , 182, 828-842.e16	56.2	485
14	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , 2020 , 9,	8.9	784
13	Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants 2020 ,		31
12	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies 2020 ,		30
11	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses 2020 ,		35
10	Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents 2020 ,		37
9	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro 2020 ,		15
8	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection 2020 ,		21
7	A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques 2020 ,		1
6	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020 , 584, 437-442	50.4	1167
5	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	289
4	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	110
3	Quantification of phosphoinositides reveals strong enrichment of PIP in HIV-1 compared to producer cell membranes. <i>Scientific Reports</i> , 2019 , 9, 17661	4.9	25
2	Synchronized HIV assembly by tunable PIP changes reveals PIP requirement for stable Gag anchoring. <i>ELife</i> , 2017 , 6,	8.9	27
1	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7